Bulletin
Investor Alert

London Markets Open in:

press release

Feb. 24, 2022, 7:15 a.m. EST

ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022

LAUSANNE, Switzerland, (BUSINESS WIRE) -- ADC Therapeutics SA /zigman2/quotes/214411413/composite ADCT -9.90% , a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, March 3, 2022 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2021 and provide business updates.

To access the live call, please dial 833-303-1198 (domestic) or +1 914-987-7415 (international) and provide conference ID 8189237. A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com . The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics /zigman2/quotes/214411413/composite ADCT -9.90% is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn .

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005180/en/

SOURCE: ADC Therapeutics SA

Investors
Eugenia Litz
ADC Therapeutics
Eugenia.Litz@adctherapeutics.com
Tel.: +44 7879 627205

Amanda Hamilton
ADC Therapeutics
amanda.hamilton@adctherapeutics.com
Tel.: +1 917 288 7023

EU Media
Alexandre Müller
Dynamics Group
amu@dynamicsgroup.ch
Tel: +41 (0) 43 268 3231

USA Media
Mary Ann Ondish
ADC Therapeutics
maryann.ondish@adctherapeutics.com
Tel.: +1 914-552-4625

COMTEX_403001381/2456/2022-02-24T07:15:27

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2022

/zigman2/quotes/214411413/composite
US : U.S.: NYSE
$ 9.28
-1.02 -9.90%
Volume: 484,046
Aug. 15, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$728.52 million
Rev. per Employee
$301,109
loading...
/zigman2/quotes/214411413/composite
US : U.S.: NYSE
$ 9.28
-1.02 -9.90%
Volume: 484,046
Aug. 15, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$728.52 million
Rev. per Employee
$301,109
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.